Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Sold by North Star Asset Management Inc.

North Star Asset Management Inc. cut its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 2.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 225,363 shares of the company's stock after selling 6,058 shares during the period. North Star Asset Management Inc. owned 0.45% of Prestige Consumer Healthcare worth $17,599,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Kestra Investment Management LLC acquired a new position in Prestige Consumer Healthcare during the fourth quarter worth $27,000. CIBC Private Wealth Group LLC lifted its stake in Prestige Consumer Healthcare by 48.9% during the fourth quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock worth $34,000 after purchasing an additional 152 shares in the last quarter. Headlands Technologies LLC acquired a new position in Prestige Consumer Healthcare during the fourth quarter worth $40,000. McIlrath & Eck LLC lifted its stake in Prestige Consumer Healthcare by 19.1% during the fourth quarter. McIlrath & Eck LLC now owns 959 shares of the company's stock worth $75,000 after purchasing an additional 154 shares in the last quarter. Finally, Johnson Financial Group Inc. acquired a new position in Prestige Consumer Healthcare during the fourth quarter worth $93,000. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, SVP Mary Beth Fritz sold 1,678 shares of the company's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the sale, the senior vice president now directly owns 17,157 shares of the company's stock, valued at approximately $1,544,130. This represents a 8.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.60% of the stock is owned by corporate insiders.

Prestige Consumer Healthcare Trading Up 0.1%

PBH stock traded up $0.06 during midday trading on Tuesday, hitting $85.81. The stock had a trading volume of 296,398 shares, compared to its average volume of 297,868. Prestige Consumer Healthcare Inc. has a 12-month low of $62.35 and a 12-month high of $90.04. The company's 50-day moving average price is $83.56 and its 200 day moving average price is $82.34. The firm has a market cap of $4.24 billion, a PE ratio of 20.09, a price-to-earnings-growth ratio of 2.69 and a beta of 0.44. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.30 by $0.02. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. The company had revenue of $296.52 million during the quarter, compared to analysts' expectations of $289.36 million. During the same period in the previous year, the company earned $1.02 EPS. The business's quarterly revenue was up 7.0% compared to the same quarter last year. On average, equities research analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on PBH. Royal Bank of Canada raised Prestige Consumer Healthcare to a "hold" rating in a report on Thursday, May 8th. Oppenheimer raised their price objective on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an "outperform" rating in a research report on Thursday, February 13th. DA Davidson lifted their price target on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a "buy" rating in a research note on Friday, February 7th. Wall Street Zen upgraded shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research report on Saturday, May 17th. Finally, Canaccord Genuity Group lifted their price objective on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a research report on Friday, February 7th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $93.33.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.